{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"HSCS","limit":50},"count":50,"signals":[{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":14,"context":"orporate governance website athttps://ir.heartsciences.com/governance-documents or may be obtained upon written request to our Office Manager at our principal executive offices. Committee members are elected by our Board of Directors, upon the Nominating and Corporate Governance Committees recommendations, and serve until their successors are elected or their earlier resignation or removal. 13 [Table of Contents](#TOC001) The cu","filed_date":"2026-03-17","accession":"0001213900-26-029099","full_text":"https://origin.rootz.global/static/filing/0001213900-26-029099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"obtained; Clinical studies may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical studies will prevent us from launching sales of modified or new pro","filed_date":"2025-07-24","accession":"0000950170-25-098326","full_text":"https://origin.rootz.global/static/filing/0000950170-25-098326.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":54,"context":"d IPO Warrants on another national securities exchange, we expect our securities would be quoted on an over-the-counter market; However, if this were to occur, our stockholders could face significant material adverse consequences, including limited availability of 26 [Table of Contents](#toc_page) market quotations for our Common Stock and IPO Warrants and reduced liquidity for the trading of our securities. In addition, in","filed_date":"2025-07-24","accession":"0000950170-25-098326","full_text":"https://origin.rootz.global/static/filing/0000950170-25-098326.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"obtained; Clinical studies may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical studies will prevent us from launching sales of modified or new pro","filed_date":"2024-07-29","accession":"0000950170-24-087271","full_text":"https://origin.rootz.global/static/filing/0000950170-24-087271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":54,"context":"securities exchange, we expect our securities would be quoted on an over-the-counter market; However, if this were 27 [Table of Contents](#toc_page) to occur, our stockholders could face significant material adverse consequences, including limited availability of market quotations for our Common Stock and IPO Warrants and reduced liquidity for the trading of our securities. In addition, in the event of such delisting, we co","filed_date":"2024-07-29","accession":"0000950170-24-087271","full_text":"https://origin.rootz.global/static/filing/0000950170-24-087271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"ance website at https://ir.heartsciences.com/governance-documents or may be obtained upon written request to our Office Manager at our principal executive offices. Committee members are elected by our board of directors, upon the Nominating and Governance Committee’s recommendations, and serve until their successors are elected or their earlier resignation or removal. 14 [Table of Contents](#TOC001) The curr","filed_date":"2023-12-08","accession":"0001213900-23-094448","full_text":"https://origin.rootz.global/static/filing/0001213900-23-094448.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"; • Clinical studies may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our 14 [Table of Contents](#toc_page) clinical studies will prevent us from lau","filed_date":"2023-07-19","accession":"0000950170-23-033424","full_text":"https://origin.rootz.global/static/filing/0000950170-23-033424.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":41,"context":"n regulatory approval and accomplish any one or more of the challenges listed above, our ability to effectively launch sales of the MyoVista into the U.S. could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations. For additional information regarding risks related to our ability to successfully develop, market and sell the MyoVista, see “&#","filed_date":"2023-07-19","accession":"0000950170-23-033424","full_text":"https://origin.rootz.global/static/filing/0000950170-23-033424.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"thereto made pursuant to Section 2(a) hereof for or in respect of such reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. (p) “Material Adverse Effect” ‎ means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and it","filed_date":"2023-03-13","accession":"0000950170-23-007467","full_text":"https://origin.rootz.global/static/filing/0000950170-23-007467.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":41,"context":"n regulatory approval and accomplish any one or more of the challenges listed above, our ability to effectively launch sales of the MyoVista into the U.S. could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations. For additional information regarding risks related to our ability to successfully develop, market and sell the MyoVista, see “&#","filed_date":"2022-07-29","accession":"0000950170-22-013513","full_text":"https://origin.rootz.global/static/filing/0000950170-22-013513.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":61,"context":"cate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern. The perception that we may not be able to continue as a going concern may have a material adverse effect on our share price and our ability to raise new capital (whether it is through the issuance of equity or debt securities or otherwise), enter into critical contractual relations with third parties an","filed_date":"2026-07-23","accession":"0001437749-26-024337","full_text":"https://origin.rootz.global/static/filing/0001437749-26-024337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":22,"context":"ime, (ii) it is expected that Mr. Simpson and David R.Wells, each a current member of the Board of Directors, shall remain on the Board of Directors after the Closing, and (iii) Andrea Childs will be named as the new Chief Executive Officer and Erik Ellingson will be named as the new Chief Financial Officer of the Company, respectively, of the Company, in each case, effective as of the Effective Time. On *June 22, 2026","filed_date":"2026-07-23","accession":"0001437749-26-024337","full_text":"https://origin.rootz.global/static/filing/0001437749-26-024337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":24,"context":"s of the Company contained in this Subscription Agreement shall be true and correct in all material respects (other than representations and warranties that are qualified as to materiality or Company Material Adverse Effect, which representations and warranties shall be true and correct in all respects) at and as of the Closing Date (except to the extent that any such representation or warranty expressly speaks as of an","filed_date":"2026-08-18","accession":"0001213900-26-091301","full_text":"https://origin.rootz.global/static/filing/0001213900-26-091301.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"; • Clinical studies may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical studies will prevent us from launching sales of modified or new pro","filed_date":"2022-07-29","accession":"0000950170-22-013513","full_text":"https://origin.rootz.global/static/filing/0000950170-22-013513.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"| | | | Clinical studies may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical studies will prevent us from launching sales of modified or new pro","filed_date":"2026-07-23","accession":"0001437749-26-024337","full_text":"https://origin.rootz.global/static/filing/0001437749-26-024337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":79,"match_count":8,"context":"inventor equals $3.5 million which, in any event, is the maximum amount we are required to pay in royalties under the MyoVista Technology Agreement. Glasgow Licensing Agreement In December 2015, we entered into a licensing agreement, which we refer to as the Glasgow Licensing Agreement, with The University Court of the University of Glasgow, under which we obtained a non-exclusive, 30 [Table of Contents](#toc_page) worldwide li","filed_date":"2022-07-29","accession":"0000950170-22-013513","full_text":"https://origin.rootz.global/static/filing/0000950170-22-013513.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":76,"match_count":7,"context":"nt or postponement thereof. 92 [Table of Contents](#toc_page) Item 11. Executive Compensation. 2025 Summary Compensation Table The following table sets forth summary compensation information for our named executive officers consisting of: our President, Chief Executive Officer and Chairman of the Board of Directors, our Chief Operating Officer and Secretary, and our Chief Financial Officer and Treasurer (collectively,","filed_date":"2025-07-24","accession":"0000950170-25-098326","full_text":"https://origin.rootz.global/static/filing/0000950170-25-098326.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":72,"match_count":9,"context":"person (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a Director of the Corporation, will act or vote on any issue or question (a **Voting Commitment**) that has not been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with","filed_date":"2025-07-01","accession":"0001213900-25-060467","full_text":"https://origin.rootz.global/static/filing/0001213900-25-060467.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":71,"match_count":7,"context":"nt or postponement thereof. 91 [Table of Contents](#toc_page) Item 11. Executive Compensation. 2024 Summary Compensation Table The following table sets forth summary compensation information for our named executive officers consisting of: our President, Chief Executive Officer and Chairman of the Board of Directors, our Chief Operating Officer and Secretary, and our Chief Financial Officer and Treasurer (collectively,","filed_date":"2024-07-29","accession":"0000950170-24-087271","full_text":"https://origin.rootz.global/static/filing/0000950170-24-087271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":67,"match_count":4,"context":"l inflows from strategic partnerships. Management can provide *no* assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do *not* include any adjustments relating to the recoverability and classification of recorded asset amounts","filed_date":"2026-09-14","accession":"0001437749-26-030319","full_text":"https://origin.rootz.global/static/filing/0001437749-26-030319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":65,"match_count":5,"context":"ness, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects. Our management will have broad discretion over the use of the net proceeds from our sale of the Lincoln Park Shares to Lincoln P","filed_date":"2024-03-05","accession":"0001213900-24-020156","full_text":"https://origin.rootz.global/static/filing/0001213900-24-020156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":65,"match_count":5,"context":"e (even if the remaining directors constitute less than a quorum of the Board of Directors), and any director so chosen shall hold office for the remainder of the term to which the director has been selected and until such directors successor shall have been elected and qualified. *No cumulative voting* Under Texas law, the right to vote cumulatively does not exist unless the certificate of formation specifically authorizes cu","filed_date":"2023-09-18","accession":"0001193125-23-236506","full_text":"https://origin.rootz.global/static/filing/0001193125-23-236506.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ior Unsecured Promissory Drawdown Loan Note (the MSW Note) with Matthews Southwest Holdings, Inc. (the Lender). The MSW Note provides for an unsecured drawdown loan of up to $1,000,000, drawn in installments consisting of (i) $250,000 on or prior to September 8, 2023, (ii) $250,000 on or prior to September 20, 2023, and (iii) further drawdowns of up to $500,000 in such amounts and such times to be mu","filed_date":"2023-09-18","accession":"0001193125-23-236506","full_text":"https://origin.rootz.global/static/filing/0001193125-23-236506.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"iving proceeds of approximately $91,000. In September 2023, the Company entered into a Senior Unsecured Promissory Drawdown Loan Note (“MSW Note”) for up to $1.0 million, drawn in installments consisting of (i) $0.25 million on or prior to September 8, 2023, (ii) ) $0.25 million on or prior to September 20, 2023, and (iii) further drawdowns of up to $0.5 million in such amounts and suc","filed_date":"2023-12-14","accession":"0000950170-23-070381","full_text":"https://origin.rootz.global/static/filing/0000950170-23-070381.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":55,"match_count":5,"context":"tors or compensation committee. 78 [Table of Contents](#toc_page) Item 11. Executive Compensation. Summary Compensation Table The following table sets forth summary compensation information for our named executive officers consisting of: our President, Chief Executive Officer and Chairman of the Board of Directors, our Chief Operating Officer and Secretary, and our Chief Financial Officer and Treasurer. The Company ha","filed_date":"2023-07-19","accession":"0000950170-23-033424","full_text":"https://origin.rootz.global/static/filing/0000950170-23-033424.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":51,"match_count":2,"context":"cate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern. The perception that we may not be able to continue as a going concern may have a material adverse effect on our share price and our ability to raise new capital (whether it is through the issuance of equity or debt securities or otherwise), enter into critical contractual relations with third parties an","filed_date":"2024-09-27","accession":"0001213900-24-082775","full_text":"https://origin.rootz.global/static/filing/0001213900-24-082775.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"l inflows from strategic partnerships. Management can provide *no* assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do *not* include any adjustments relating to the recoverability and classification of recorded asset amounts","filed_date":"2026-03-16","accession":"0001437749-26-008399","full_text":"https://origin.rootz.global/static/filing/0001437749-26-008399.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2025-12-15","accession":"0001193125-25-319203","full_text":"https://origin.rootz.global/static/filing/0001193125-25-319203.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2025-09-11","accession":"0001468492-25-000010","full_text":"https://origin.rootz.global/static/filing/0001468492-25-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2025-03-13","accession":"0000950170-25-038699","full_text":"https://origin.rootz.global/static/filing/0000950170-25-038699.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2024-12-16","accession":"0000950170-24-136607","full_text":"https://origin.rootz.global/static/filing/0000950170-24-136607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2024-09-12","accession":"0000950170-24-105914","full_text":"https://origin.rootz.global/static/filing/0000950170-24-105914.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"al commercial revenue in Fiscal 2024. 6 Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or","filed_date":"2024-03-14","accession":"0000950170-24-031457","full_text":"https://origin.rootz.global/static/filing/0000950170-24-031457.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"ct is defective as manufactured. Historically, the actual product returns have been immaterial to the Companys financial statements. The Company elected to treat shipping and handling costs as a fulfillment cost and included them in 10 the cost of goods sold as incurred. Costs associated with product sales include commissions. The Company applies the practical expedient and recognizes commissions as","filed_date":"2024-03-14","accession":"0000950170-24-031457","full_text":"https://origin.rootz.global/static/filing/0000950170-24-031457.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"ing proceeds of approximately $0.2 million. In September 2023, the Company entered into a Senior Unsecured Promissory Drawdown Loan Note (“MSW Note”) for up to $1 million, drawn in installments consisting of (i) $0.25 million on or prior to September 8, 2023, (ii) ) $0.25 million on or prior to September 20, 2023, and (iii) further drawdowns of up to $0.5 million in such amounts and suc","filed_date":"2023-09-14","accession":"0000950170-23-048168","full_text":"https://origin.rootz.global/static/filing/0000950170-23-048168.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":44,"match_count":3,"context":"erial commercial revenue in Fiscal 2024. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or","filed_date":"2023-12-14","accession":"0000950170-23-070381","full_text":"https://origin.rootz.global/static/filing/0000950170-23-070381.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":44,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2023-09-14","accession":"0000950170-23-048168","full_text":"https://origin.rootz.global/static/filing/0000950170-23-048168.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":44,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. Subsequent to the quarter ended January 31, 2023, in March 2023, the Company entered into a purchase agreement and a registration rights agreement with an","filed_date":"2023-03-16","accession":"0000950170-23-008432","full_text":"https://origin.rootz.global/static/filing/0000950170-23-008432.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":44,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. The condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts o","filed_date":"2022-12-15","accession":"0000950170-22-026616","full_text":"https://origin.rootz.global/static/filing/0000950170-22-026616.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":44,"match_count":3,"context":"tal inflows from strategic partnerships. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements. These unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the am","filed_date":"2022-09-12","accession":"0000950170-22-018344","full_text":"https://origin.rootz.global/static/filing/0000950170-22-018344.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":42,"match_count":4,"context":"stock, including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. For additional information regarding compensation arrangements for our named executive officers and directors, see “Executive Compensation.” Related Party Transactions $130K Note On August 12, 2019, we entered into an unsecured drawdown convertible promissory note (the “$130K Not","filed_date":"2024-09-27","accession":"0001213900-24-082775","full_text":"https://origin.rootz.global/static/filing/0001213900-24-082775.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":39,"match_count":3,"context":"e (even if the remaining directors constitute less than a quorum of the Board of Directors), and any director so chosen shall hold office for the remainder of the term to which the director has been selected and until such director’s successor shall have been elected and qualified. No cumulative voting Under Texas law, the right to vote cumulatively does not exist unless the certificate of formation specifically authoriz","filed_date":"2024-03-05","accession":"0001213900-24-020156","full_text":"https://origin.rootz.global/static/filing/0001213900-24-020156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"ave an exercise price of $4.37 per share, will vest as follows: one-fourth of the respective Director Options vested on October9, 2025 and the remaining Director Options will vest in three equal installments thereafter on each subsequent three-month anniversary of such date. On December3, 2025, our Board of Directors also approved an amendment to the Plan to increase the maximum aggregate number of s","filed_date":"2026-03-17","accession":"0001213900-26-029099","full_text":"https://origin.rootz.global/static/filing/0001213900-26-029099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"ons to each independent director, which options vest over a period of twelve months, with one-fourth vesting on June 20, 2023 and the remaining three-fourths vesting in three equal installments thereafter on each subsequent three-month anniversary of such date, provided that such director continues to serve as our director on each vesting date. At the direction of the Compensation Commi","filed_date":"2023-12-08","accession":"0001213900-23-094448","full_text":"https://origin.rootz.global/static/filing/0001213900-23-094448.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":24,"match_count":3,"context":"is in active discussions for MyoVista InsightsTM to be implemented in test sites during 2025, which followed on-scheduled completion of Phase 1, in December 2024. MyoVista Insights is a cloud-native, cybersecure modern technology stack operating on a device agnostic basis for the millions of ECGs in place today. It is intended to radically upgrade ECG reporting and does not require regulatory clearance","filed_date":"2025-05-19","accession":"0000950170-25-074598","full_text":"https://origin.rootz.global/static/filing/0000950170-25-074598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":24,"match_count":3,"context":"is in active discussions for MyoVista InsightsTM to be implemented in test sites during 2025, which followed on-scheduled completion of Phase 1, in December 2024. MyoVista Insights is a cloud-native, cybersecure modern technology stack operating on a device agnostic basis for the millions of ECGs in place today. It is intended to radically upgrade ECG reporting and does not require regulatory clearance","filed_date":"2025-03-13","accession":"0000950170-25-038762","full_text":"https://origin.rootz.global/static/filing/0000950170-25-038762.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":24,"match_count":3,"context":"the end of the calendar year. HeartSciences has invested millions of dollars in 2024 to develop a cloud-native ECG reporting system which will run on Amazon Web Services (AWS). MyoVista Insights is a cybersecure modern technology stack which is intended to radically upgrade ECG reporting. Phase 1 does not require regulatory clearance (as it is reporting based) and the Company is in discussions for this","filed_date":"2024-12-16","accession":"0000950170-24-136647","full_text":"https://origin.rootz.global/static/filing/0000950170-24-136647.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"ct is defective as manufactured. Historically, the actual product returns have been immaterial to the Companys financial statements. The Company elected to treat shipping and handling costs as a fulfillment cost and included them in the cost of goods sold as incurred. Costs associated with product sales include commissions. The Company applies the practical expedient and recognizes commissions as exp","filed_date":"2024-12-16","accession":"0000950170-24-136607","full_text":"https://origin.rootz.global/static/filing/0000950170-24-136607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":24,"match_count":3,"context":"a0;       each of our principal executive officer and the next two most highly compensated executive officers as of April 30, 2024 (the “Named Executive Officers”); •        our other executive officers; and •        all of our","filed_date":"2024-09-18","accession":"0001213900-24-079949","full_text":"https://origin.rootz.global/static/filing/0001213900-24-079949.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HSCS","company":"HeartSciences Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"ct is defective as manufactured. Historically, the actual product returns have been immaterial to the Companys financial statements. The Company elected to treat shipping and handling costs as a fulfillment cost and included them in the cost of goods sold as incurred. Costs associated with product sales include commissions. The Company applies the practical expedient and recognizes commissions as exp","filed_date":"2024-09-12","accession":"0000950170-24-105914","full_text":"https://origin.rootz.global/static/filing/0000950170-24-105914.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"1fa5b92de22bb9377b7ccb111df2cefcff1d80783f311fe711539c5afe1ace2a","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"65afff7aeec926b9c1c44dc3db779a777b523d58b14ea0ffc50cc49bf89b703b","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":14,"hourly_limit":500,"remaining":486,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}